Bristol-Myers Squibb CompanyViés de alta
BMY Long Term Long
Healthy pipeline.
Sitting at 3.32% yield and 8.62 P/E (norm is 18.65 and 5Y norm is 11.17) with earnings growth rate approx. 6.18% since 2000 but has increased to 15-16% if you look at the 10Y and 5Y norms.
Estimates are for about 4-6% the next 2 years.
A+ Credit Rating
48LT Debt to Cap
PT $96 by 2023 using a 7% earnings growth rate and 12 P/E
HUGE saucer pattern -- technically.
Sitting at 3.32% yield and 8.62 P/E (norm is 18.65 and 5Y norm is 11.17) with earnings growth rate approx. 6.18% since 2000 but has increased to 15-16% if you look at the 10Y and 5Y norms.
Estimates are for about 4-6% the next 2 years.
A+ Credit Rating
48LT Debt to Cap
PT $96 by 2023 using a 7% earnings growth rate and 12 P/E
HUGE saucer pattern -- technically.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.